JPMorgan analyst Rachel Vatnsdal lowered the firm’s price target on 10x Genomics (TXG) to $12 from $14 and keeps a Neutral rating on the shares ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback